News Sentiment

BIO-B sentiment intelligence

Bio-Rad Laboratories Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 50 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 298.50 Week of 10 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

79/100 classification confidence.

Company focus 40

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+0.7% over one week, -1.9% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Entera Bio (NASDAQ: ENTX) CEO swaps cash for stock-settled RSUs

Market Reaction

Balanced read

48/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 79/100 classification
One-week reaction 0.7% Price digesting
Trend fit Trend inactive -1.9% over four weeks
Fair value -1.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 3
Neutral 45
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 40
Industry context 10
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
MarketBeat 11
Stock Titan 8
simplywall.st 4
StockStory 3
ad-hoc-news.de 1
TradingView 1
Finviz 1

Event Lens

What the news is about

Classified themes
Earnings 28
Market update 14
Analyst action 3
Deals and strategy 2
Guidance 2
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
TradingView Direct company coverage

BUWA Forecast — Price Target — Prediction for 2027

This article provides a forecast for Bio-Rad Laboratories, Inc. Class A (BUWA) stock, including price targets from analysts and historical performance. It details the company's financials, earnings reports, revenue, net income, and current market capitalization. The article also

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 19:10
Source
TradingView
Finviz Direct company coverage

BIO

This article provides comprehensive financial data, news, and analyst ratings for Bio-Rad Laboratories Inc. (BIO). It includes key metrics such as stock price, market capitalization, P/E ratio, and recent insider transactions. The news section highlights recent events like activi

Tone
Neutral 50/100
Event
Analyst action
Published
28 May 2026 19:39
Source
Finviz
Ad Hoc News Direct company coverage

Bio-Rad Laboratories stock (US09062X1037): sector focus as Elliott stake and price gains keep NYSE l

Bio-Rad Laboratories shares are trading firmly above USD 300 on the NYSE, attracting investor attention due to an activist stake by Elliott Investment Management and recent price target updates. The company, a mid-cap life-science tools provider, has seen over 30% gains in the la

Tone
Neutral 50/100
Event
Analyst action
Published
28 May 2026 14:40
Source
Ad Hoc News
Stock Titan Direct company coverage

Bio-Rad (NYSE: BIO) EVP Engelhardt sells 550 A shares in open market

Eva Anette Engelhardt, EVP and President of the Clinical Diagnostics Group at Bio-Rad Laboratories (NYSE: BIO), reported an open-market sale of 550 shares of Bio-Rad A Common Stock on May 11, 2026, at a price of $246.54 per share. Following this transaction, Engelhardt directly h

Tone
Neutral 50/100
Event
Market update
Published
27 May 2026 20:09
Source
Stock Titan
Market source Direct company coverage

Ariel Investments Re-added Bio-Rad Laboratories (BIO) as Strong Margins and Market Leadership Stand Out

Ariel Investments' Ariel Focus Fund re-added Bio-Rad Laboratories (BIO) to its portfolio, highlighting the company's strong financial profile, diversified market footprint, and market leadership in life science research and clinical diagnostics. The fund emphasized Bio-Rad's risi

Tone
Neutral 50/100
Event
Market update
Published
05 May 2026 17:09
Source
Market source
Simply Wall Street Direct company coverage

Bio-Rad Laboratories (NYSE:BIO) - Stock Analysis

This article provides a stock analysis of Bio-Rad Laboratories (NYSE:BIO), highlighting its valuation, future growth, past performance, financial health, and recent news. The company, which develops and distributes life science research and clinical diagnostic products, is curren

Tone
Neutral 50/100
Event
Market update
Published
04 May 2026 09:40
Source
Simply Wall Street
MarketBeat Direct company coverage

Bio-Rad Laboratories (NYSE:BIO.B) Posts Earnings Results

Bio-Rad Laboratories (NYSE:BIO.B) announced its quarterly earnings, reporting an EPS of $1.89. The company demonstrated strong profitability with a net margin of 29.42% and a return on equity of 3.86%. Shares traded up by $22.45 to $299.45 following the report, with the company m

Tone
Neutral 50/100
Event
Earnings
Published
30 Apr 2026 21:39
Source
MarketBeat
Stock Titan Direct company coverage

Bio-Rad (NYSE: BIO) posts Q1 loss and trims 2026 guidance

Bio-Rad Laboratories reported a Q1 2026 net sales increase of 1.1% year-over-year to $592.1 million, but a 4.2% currency-neutral decrease, resulting in a large GAAP net loss of $527.1 million primarily due to an investment fair value change. The company also lowered its full-year

Tone
Neutral 50/100
Event
Guidance
Published
30 Apr 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Huge Sartorius loss drives Bio-Rad (NYSE: BIO) Q1 2026 net loss

Bio-Rad Laboratories reported a net loss of $527.1 million in Q1 2026, primarily due to a $738.2 million fair-value loss from equity securities and a loan receivable, including a significant $727.7 million holding loss on its investment in Sartorius AG. Despite this, net sales sl

Tone
Neutral 50/100
Event
Market update
Published
30 Apr 2026 20:38
Source
Stock Titan
Investing.com Australia Direct company coverage

Bio-Rad earnings on deck: Can margins recover after rough 2025?

Bio-Rad Laboratories is set to report its first-quarter earnings, with investors keenly watching for signs of margin recovery after a challenging 2025 where performance fell below expectations. Analysts anticipate earnings of $2.01 per share on $591.28 million in revenue. Key fac

Tone
Neutral 50/100
Event
Earnings
Published
30 Apr 2026 14:38
Source
Investing.com Australia
Stock Titan Direct company coverage

Bio-Rad will release Q1 results after market close on April 30

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) announced it will report its first-quarter 2026 financial results on Thursday, April 30, 2026, after the market closes. Management will host a conference call at 2:00 PM Pacific Time (5:00 PM Eastern Time) to discuss the results, w

Tone
Neutral 50/100
Event
Earnings
Published
16 Apr 2026 15:09
Source
Stock Titan
Stock Titan Direct company coverage

Vanguard disaggregates holdings; Bio‑Rad Labs (NYSE: BIO) shows 0 shares

The Vanguard Group filed an amended Schedule 13G/A for Bio-Rad Laboratories Inc. (NYSE: BIO), reporting beneficial ownership of 0 shares (0%) due to an internal realignment on January 12, 2026. This disaggregation of holdings means certain Vanguard subsidiaries will now report th

Tone
Neutral 50/100
Event
Market update
Published
26 Mar 2026 20:38
Source
Stock Titan